A Trial of Ciclesonide in Adults With Mild-to-moderate COVID-19

A Trial of Ciclesonide to Assess The Antiviral Effect for Adults With Mild-to-moderate COVID-19

According to In vitro studies, ciclesonide showed good antiviral activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Although some cases were reported for the clinical effectiveness of ciclesonide in the treatment of COVID-19, there is no clinical trial to evaluate the antiviral effect on the reduction of viral load in patients with COVID-19. In this study, we aimed to investigate whether ciclesonide inhalation could eradicate SARS-CoV-2 compared to standard supportive care in patients with mild COVID-19.

Inclusion Criteria:

• Patients with mild COVID-19 (NEWS scoring system 0-4)
• Patient within 7 days from symptom onset or Patient within 48 hous after laboratory diagnosis (SARS-CoV-2 RT-PCR)

Exclusion Criteria:

• Hypoxia (SaO2 <95%)
• Unable to take oral medication
• Unable to use inhaler
• Pregnancy or breast feeding
• Immunocompromising conditions
• Moderate/severe renal dysfunction : creatinine clearance (CCL) < 30 mL/min
• Moderate/severe liver dysfunction: AST or ALT > 5 times upper normal limit
• Asthma or chronic obstructive lung disease